Even if there are sales of the new cloud products, there will be an ongoing impact on revenue and NPAT. Licence revenue is brought to account immediately (e.g. $1M for 3 year licence is recognised at time of sale). You can't recognise SaaS revenue that way, immediate hit to revenue and NPAT, but the more important metric then becomes ARR from SaaS sales. There will be a pain period of transition to SaaS. Problem is the company is providing no real transparency on how these SaaS deals are going.
- Forums
- ASX - By Stock
- Ann: Market Update - Continuous Disclosure
Even if there are sales of the new cloud products, there will be...
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IRI (ASX) to my watchlist
(20min delay)
|
|||||
Last
40.5¢ |
Change
0.005(1.25%) |
Mkt cap ! $70.71M |
Open | High | Low | Value | Volume |
40.0¢ | 40.5¢ | 39.0¢ | $41.06K | 103.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 954 | 39.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.5¢ | 39070 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 954 | 0.390 |
2 | 5597 | 0.385 |
3 | 68873 | 0.380 |
2 | 6700 | 0.370 |
2 | 30000 | 0.365 |
Price($) | Vol. | No. |
---|---|---|
0.405 | 39070 | 1 |
0.410 | 1600 | 1 |
0.420 | 4800 | 1 |
0.425 | 2000 | 1 |
0.430 | 5000 | 1 |
Last trade - 15.59pm 06/05/2024 (20 minute delay) ? |
|
|||||
Last
39.5¢ |
  |
Change
0.005 ( 4.82 %) |
|||
Open | High | Low | Volume | ||
40.0¢ | 40.5¢ | 39.5¢ | 9240 | ||
Last updated 15.44pm 06/05/2024 ? |
Featured News
IRI (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online